Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance

GILEAD SCIENCES, INC.

2021-Q2 EPS reported $2.58 revenue$12,640,000,000

Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).
GAAP diluted EPS $1.21 (vs. loss of $2.66); non-GAAP diluted EPS $1.87 (+68%).
Veklury sales $829M; HIV sales $3.9B (-2%); Biktarvy up 24%; HCV up 23%.
FY2021 guidance: product sales $24.4-25.0B; Veklury $2.7-3.1B (prev $2.0-3.0B); non-GAAP EPS $6.90-7.25.
Quarterly dividend $0.71 payable Sep 29, record Sep 15; pipeline updates include lenacapavir NDA filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.